Larimar Therapeutics, Inc.
nomlabofusp
Friedreich's ataxia
Resolved
133days ago
Advisory committee · Feb 24, 2026
What's at stake
An FDA advisory committee reviews nomlabofusp for Friedreich's ataxia around Feb 24, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Following a recent Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program meeting with FDA and review of preliminary clinical data for the nomlabofusp program, Larimar announced continued alignment with the FD”